The coronavirus disease 19 (COVID-19) ongoing pandemic, caused by SARS-CoV2 has infected millions of people around the world and has caused over 4 million deaths. The pandemic has also caused significant economic and social disruptions.
Since the emergence of COVID-19 in 2019, our lab has been focused on understanding the antibody responses induced by both infection and vaccination, as well as profiling monoclonal antibodies.
Our work has focused on key areas including:
Vulnerable populations, such as the elderly. See Selva, K.J., et al., Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun, 2021. 12(1): p. 2037.
Mucosal respones. See Selva, Kevin J., et al. "Mucosal antibody responses following Vaxzevria vaccination." Immunology and Cell Biology (2023).
Unique isotype profiling. See Davis, Samantha K., et al. "Heterologous SARS‐CoV‐2 IgA neutralising antibody responses in convalescent plasma." Clinical & Translational Immunology 11.10 (2022): e1424. (Awarded 2022 CTI Publication of the Year)
SARS-CoV-2 variants. See Haycroft, Ebene R., et al. "Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants." Medical Microbiology and Immunology 212.4 (2023): 291-305.
For prospective students, please email for currently available projects.